A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

Stopped Due to poor enrollment sponsor terminated early after enrolling 9 in Cohort 1 and no enrollment in Cohorts 2 and 3.

Conditions

• Schizophrenia
• Schizoaffective Disorder

Interventions

• DRUG: Aripiprazole
• DRUG: Olanzapine
• DRUG: Paliperidone
• DRUG: Quetiapine
• DRUG: Risperidone

Sponsor

Janssen Research & Development, LLC